Why wouldn't you lock in some profits- stock spiked over $6B on phase 2 data for CF. Spike also related to short covering and other trading dynamics. Sold some shares here also- no choice on that kind of move with blue chip biotech. Added to my large position in INSM - upcoming phase 3 data also in CF in July. Mkt cap is still small under $250MM mkt cap so lots of upside as they also have phase 2 data in the FAll in NTM pulmonary infections. . Stock will also be added to Russell Index in June (Index guys have to buy over 3 mil shrs before June...).